Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study - 27/10/22
, Tristan Millington, PhD c, *, Thiago Cerqueira-Silva, MD d, f, Chris Robertson, ProfPhD g, Vinicius de Araújo Oliveira, MD a, Juracy B S Júnior, MSc e, Flávia J O Alves, PhD a, Gerson O Penna, PhD h, Srinivasa Vital Katikireddi, PhD i, Viviane S Boaventura, ProfPhD d, f, Guilherme L Werneck, ProfDSc j, k, Neil Pearce, ProfPhD l, Colin McCowan, PhD m, Christopher Sullivan, PhD g, Utkarsh Agrawal, PhD m, Zoe Grange, PhD g, Lewis D Ritchie, MD n, Colin R Simpson, PhD o, Aziz Sheikh, ProfMD c, Mauricio L Barreto, ProfMD a, Igor Rudan, ProfPhD c, †, Manoel Barral-Netto, ProfMD a, d, †, Enny S Paixão, PhD l, †
Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.
Connectez-vous pour en bénéficier!
Summary |
Background |
Little is known about vaccine effectiveness over time among adolescents, especially against the SARS-CoV-2 omicron (B.1.1.529) variant. This study assessed the associations between time since two-dose vaccination with BNT162b2 and the occurrence of symptomatic SARS-CoV-2 infection and severe COVID-19 among adolescents in Brazil and Scotland.
Methods |
We did test-negative, case-control studies in adolescents aged 12–17 years with COVID-19-related symptoms in Brazil and Scotland. We linked records of SARS-CoV-2 RT-PCR and antigen tests to national vaccination and clinical records. We excluded tests from individuals who did not have symptoms, were vaccinated before the start of the national vaccination programme, received vaccines other than BNT162b2 or a SARS-CoV-2 booster dose of any kind, or had an interval between their first and second dose of fewer than 21 days. Additionally, we excluded negative SARS-CoV-2 tests recorded within 14 days of a previous negative test, negative tests recorded within 7 days after a positive test, any test done within 90 days after a positive test, and tests with missing sex and location information. Cases (SARS-CoV-2 test-positive adolescents) and controls (test-negative adolescents) were drawn from a sample of individuals in whom tests were collected within 10 days of symptom onset. We estimated the adjusted odds ratio and vaccine effectiveness against symptomatic COVID-19 for both countries and against severe COVID-19 (hospitalisation or death) for Brazil across fortnightly periods.
Findings |
We analysed 503 776 tests from 2 948 538 adolescents in Brazil between Sept 2, 2021, and April 19, 2022, and 127 168 tests from 404 673 adolescents in Scotland between Aug 6, 2021, and April 19, 2022. Vaccine effectiveness peaked at 14–27 days after the second dose in both countries during both waves, and was significantly lower against symptomatic infection during the omicron-dominant period in Brazil (64·7% [95% CI 63·0–66·3]) and in Scotland (82·6% [80·6–84·5]), than it was in the delta-dominant period (80·7% [95% CI 77·8–83·3] in Brazil and 92·8% [85·7–96·4] in Scotland). Vaccine efficacy started to decline from 27 days after the second dose for both countries, reducing to 5·9% (95% CI 2·2–9·4) in Brazil and 50·6% (42·7–57·4) in Scotland at 98 days or more during the omicron-dominant period. In Brazil, protection against severe disease remained above 80% from 28 days after the second dose and was 82·7% (95% CI 68·8–90·4) at 98 days or more after receiving the second dose.
Interpretation |
We found waning vaccine protection of BNT162b2 against symptomatic COVID-19 infection among adolescents in Brazil and Scotland from 27 days after the second dose. However, protection against severe COVID-19 outcomes remained high at 98 days or more after the second dose in the omicron-dominant period. Booster doses for adolescents need to be considered.
Funding |
UK Research and Innovation (Medical Research Council), Scottish Government, Health Data Research UK BREATHE Hub, Fiocruz, Fazer o Bem Faz Bem programme, Brazilian National Research Council, and Wellcome Trust.
Translation |
For the Portuguese translation of the abstract see Supplementary Materials section.
Le texte complet de cet article est disponible en PDF.Plan
Vol 22 - N° 11
P. 1577-1586 - novembre 2022 Retour au numéro
Article précédent
- Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial
- Raburn M Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, Heather McFall, Michelle Robinson, Joyce S Plested, Mingzhu Zhu, Shane Cloney-Clark, Bin Zhou, Gordon Chau, Andreana Robertson, Sonia Maciejewski, Holly L Hammond, Lauren Baracco, James Logue, Matthew B Frieman, Gale Smith, Nita Patel, Gregory M Glenn, Novavax 2019nCoV101 Study Group, Mark Adams, Mark Arya, Eugene Athan, Ira Berger, Paul Bradley, Toby Briskin, Richard Glover II, Paul Griffin, Joshua Kim, Scott Kitchener, Terry Klein, Amber Leah, Indika Leelasena, Charlotte Lemech, Jason Lickliter, Mary Beth Manning, Fiona Napier-Flood, Paul Nugent, Susan Thackwray, Mark Turner
- Estimating the effect of the wMel release programme on the incidence of dengue and chikungunya in Rio de Janeiro, Brazil: a spatiotemporal modelling study
- Gabriel Ribeiro dos Santos, Betina Durovni, Valeria Saraceni, Thais Irene Souza Riback, Sofia B Pinto, Katherine L Anders, Luciano A Moreira, Henrik Salje
Bienvenue sur EM-consulte, la référence des professionnels de santé.